Lunai Bioworks Inc (LNAI) is a health technology company that is developing AI-based software and test kits for cancer detection and diagnosis. The company, operating under the Renovaro Cube brand, has not yet disclosed commercial revenue in the excerpts from its 10-K filed September 29, 2025. Renovaro Cube's platform applies multi-omic data analysis, including epigenomics, transcriptomics, metabolomics, genomics, and clinical data, to identify cancer biomarkers and generate machine-learning-validated diagnostic panels. Its proprietary panel mining technique combines individual biomarkers into composite panels validated across independent data sets. A subsidiary, BioSymetrics, contributes additional AI capabilities. Target customers are healthcare providers, hospitals, clinics, and physicians. Products intended for disease diagnosis will require FDA clearance or approval before commercialization. The company is pre-revenue in its commercialization stage and has funded operations through secured promissory notes, including notes issued to RS Bio and subsequently assigned to Rene Sindlev, bearing 12% annual interest.

Revenue model

No commercial revenue is disclosed in the filing excerpts. The company is in a pre-commercial stage and has raised operating capital through 5% original issue discount secured promissory notes bearing 12% annual interest, with principal amounts including $105,263, $526,315, and $1,000,000 in separate agreements (as of June 30, 2025).

Products and services

Renovaro Cube is developing an AI platform and associated test kits for early cancer detection, cancer recurrence monitoring, and, in time, diagnosis of other rare diseases. The platform uses multi-omic data analysis and a proprietary panel mining technique to generate composite biomarker panels. An Explainable AI feature provides human-understandable outputs for clinical decision support. Multi-modal data analysis integrates genomics, imaging, phenotypic, and wearable data.

Customers and end markets

Target customers are healthcare providers, hospitals, clinics, and physicians. End markets are clinical oncology diagnostics and cancer treatment selection. Reimbursement from governments, health insurers, and third-party payors is identified as a key commercialization dependency.

Value-chain role

Renovaro Cube operates as a health technology developer and, prospectively, a diagnostic product commercializer. It relies on third-party manufacturing and supply relationships for physical products and collaborates with clinical and research teams for validation. Intellectual property includes owned patents and licenses from third-party licensors.

Geographic exposure

The company is incorporated and files with the U.S. SEC. Patent activity spans the U.S. Patent and Trademark Office, the European Patent Office, and the United Kingdom Intellectual Property Office, suggesting intended multi-jurisdictional operations. No specific revenue geography is disclosed.

Source: SEC 10-K, filed 2025-09-29

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Annovis Bio Inc Rezolute Inc Atossa Therapeutics Inc Candel Therapeutics Inc Biostax Corp. MediciNova Inc Shattuck Labs Inc